<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491217</url>
  </required_header>
  <id_info>
    <org_study_id>HM-OXL-201</org_study_id>
    <nct_id>NCT01491217</nct_id>
  </id_info>
  <brief_title>A Study of Oraxol® in Gastric Cancer Patients</brief_title>
  <official_title>A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to determine the maximum tolerated dose (MTD) and
      recommend dose (RD) of Oraxol® in Phase I and to determine the objective response rate of
      Oraxol® in Phase II.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administration Schedule: 1 cycle of Oraxol® is 28 days and Oraxol® is administrated twice a
      week, total 6 times per cycle (day 1,2,8,9,15 and 16).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity evaluation (safety evaluation)</measure>
    <time_frame>DLT will be assessed on 28days of 1 cycle</time_frame>
    <description>Toxicity will be evaluated by medical history, vital signs, physical examination and laboratory tests performed during the screening period (D-28 to D0) and treatment period based on NCI-CTCAE (version 3.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate(ORR) evaluation</measure>
    <time_frame>Response will be evaluated every Cycle 2(8weeks)</time_frame>
    <description>It is measured up to confirmation of tumor response(CR, PR)
Tumor response will be evaluated by RECIST v1.0.</description>
  </primary_outcome>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Advanced Metastatic Gastric Cancer</condition>
  <condition>Recurrent Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must histologically or cytologically be diagnosed to have an advanced solid
             cancer. (phaseI)

          2. Advanced/metastatic/recurred gastric cancer(PhaseII)

          3. ECOG performance status ≤ 2

          4. Patients have proper bone marrow, kidney, liver function and patients do not have
             remarkable dysfunction of heart and lung: WBC≥4000/mm3; Platelet ≥100,000/mm3;
             Hemoglobin≥9.0g/dL; ANC≥ 1,500 /mm3; Creatinine ≤ 1.5mg/dL; AST/ALT/ALP ≤ 3 X the
             upper limit of normal; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X the upper limit of
             normal but &lt;5 if liver or bone metastasis is present

        Exclusion Criteria:

          1. Patients with blood tumor (ex, leukemia), uncontrolled infectious disease, neurologic
             disorders, metastasis to CNS or ileus (patients requiring non-oral administration of
             anti-biotics to treat active bacterial infection are nor eligible, but patients can
             participate in the trial after complete eradication or control of the infection)

          2. Patients who have received bone marrow transplant or are to receive bone marrow
             transplant.

          3. Patients who had the medical history of atrial or ventricular arrhythmia or congestive
             heart failure or received medical treatment for myocardial infarction within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yung-Jue Bang, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Mi Park, Ph.D</last_name>
    <email>kmpark@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung-Jue Bang, M.D, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oraxol®</keyword>
  <keyword>oral paclitaxel</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>HM30181A</keyword>
  <keyword>MTD</keyword>
  <keyword>DLT</keyword>
  <keyword>RD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 15, 2015</submitted>
    <returned>June 5, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

